| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $125K | — | -59.4% |
| SG&A Expense | $1.6M | — | -5.4% |
| Operating Income | -$1.7M | — | +13.8% |
| Pre-tax Income | -$2.4M | — | -385.7% |
| Net Income | -$2.4M | — | -385.7% |
| EPS (Basic) | -$2.42 | — | -1110.0% |
| EPS (Diluted) | -$2.42 | — | -1110.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.3M | -34.5% | -74.5% |
| Short-term Investments | $3.4M | +7.8% | +37.8% |
| Current Assets | $8.0M | -13.5% | -49.4% |
| Total Assets | $9.5M | -16.8% | -41.3% |
| Current Liabilities | $1.6M | -4.0% | -77.9% |
| Total Liabilities | $1.6M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.1M | — | +25.8% |
| Investing Cash Flow | -$219K | — | -112.5% |
| Financing Cash Flow | -$404K | — | +88.6% |
| -83.6% |
| Stockholders' Equity | $1.2M | -68.2% | -60.7% |